Critical Role of Toll-Like Receptor Signaling in NK Cell Activation
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
NKG2D Signaling Within the Pancreatic Islets Reduces NOD Diabetes and Increases Protective Central Memory CD81 T-Cell Numbers
Diabetes Volume 69, August 2020 1749 NKG2D Signaling Within the Pancreatic Islets Reduces NOD Diabetes and Increases Protective Central Memory CD81 T-Cell Numbers Andrew P. Trembath,1 Kelsey L. Krausz,1 Neekun Sharma,1 Ivan C. Gerling,2 Clayton E. Mathews,3 and Mary A. Markiewicz1 Diabetes 2020;69:1749–1762 | https://doi.org/10.2337/db19-0979 NKG2D is implicated in autoimmune diabetes. How- The immune receptor NKG2D, expressed by natural killer ever, the role of this receptor in diabetes pathogenesis (NK) cells and subsets of T cells (1–5), is implicated in type IMMUNOLOGY AND TRANSPLANTATION is unclear owing to conflicting results with studies in- 1 diabetes development. However, its role in disease pro- volving global inhibition of NKG2D signaling. We found gression remains unclear, with conflicting reports describ- that NKG2D and its ligands are present in human pan- ing pathogenic (6,7), nonpathogenic (8), and protective (9) creata, with expression of NKG2D and its ligands in- effects of NKG2D signaling. creased in the islets of patients with type 1 diabetes. NKG2D recognizes multiple NKG2D ligands in both To directly assess the role of NKG2D in the pancreas, we humans and mice. These are endogenous ligands, which generated NOD mice that express an NKG2D ligand in are all distantly related to MHC class I in sequence, and are b-islet cells. Diabetes was reduced in these mice. The generally believed to be functionally redundant (10,11). reduction corresponded with a decrease in the effector 1 NKG2D ligands are considered stress ligands, with their to central memory CD8 T-cell ratio. -
Delineation of Natural Killer Cell Differentiation from Myeloid Progenitors in Human
Delineation of Natural Killer Cell Differentiation from Myeloid Progenitors in Human The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Chen, Qingfeng, Weijian Ye, Wei Jian Tan, Kylie Su Mei Yong, Min Liu, Shu Qi Tan, Eva Loh, et al. “Delineation of Natural Killer Cell Differentiation from Myeloid Progenitors in Human.” Scientific Reports 5 (October 12, 2015): 15118. As Published http://dx.doi.org/10.1038/srep15118 Publisher Nature Publishing Group Version Final published version Citable link http://hdl.handle.net/1721.1/100500 Terms of Use Creative Commons Attribution Detailed Terms http://creativecommons.org/licenses/by/4.0/ www.nature.com/scientificreports OPEN Delineation of Natural Killer Cell Differentiation from Myeloid Progenitors in Human Received: 01 July 2015 1,* 2,3,* 2 1 1 4 Accepted: 16 September 2015 Qingfeng Chen , Weijian Ye , Wei Jian Tan , Kylie Su Mei Yong , Min Liu , Shu Qi Tan , 5 5,6 4,6 2,3 2,7 Published: 12 October 2015 Eva Loh , Kenneth TE Chang , Thiam Chye Tan , Peter R Preiser & Jianzhu Chen Understanding of natural killer (NK) cell development in human is incomplete partly because of limited access to appropriate human tissues. We have developed a cytokine-enhanced humanized mouse model with greatly improved reconstitution and function of human NK cells. Here we report the presence of a cell population in the bone marrow of the cytokine-treated humanized mice that express both NK cell marker CD56 and myeloid markers such as CD36 and CD33. The CD56+CD33+CD36+ cells are also found in human cord blood, fetal and adult bone marrow. -
TLR8-Dependent Immune Responses Stimulating Sequence-Specific
Identification of RNA Sequence Motifs Stimulating Sequence-Specific TLR8-Dependent Immune Responses This information is current as Alexandra Forsbach, Jean-Guy Nemorin, Carmen Montino, of September 28, 2021. Christian Müller, Ulrike Samulowitz, Alain P. Vicari, Marion Jurk, George K. Mutwiri, Arthur M. Krieg, Grayson B. Lipford and Jörg Vollmer J Immunol 2008; 180:3729-3738; ; doi: 10.4049/jimmunol.180.6.3729 Downloaded from http://www.jimmunol.org/content/180/6/3729 References This article cites 55 articles, 25 of which you can access for free at: http://www.jimmunol.org/content/180/6/3729.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 28, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Identification of RNA Sequence Motifs Stimulating Sequence-Specific TLR8-Dependent Immune Responses1 Alexandra Forsbach,* Jean-Guy Nemorin,† Carmen Montino,* Christian Mu¨ller,* Ulrike Samulowitz,* Alain P. -
Toll-Like Receptors and Relevant Emerging Therapeutics with Reference to Delivery Methods
pharmaceutics Review Toll-Like Receptors and Relevant Emerging Therapeutics with Reference to Delivery Methods Nasir Javaid, Farzana Yasmeen and Sangdun Choi * Department of Molecular Science and Technology, Ajou University, Suwon 16499, Korea * Correspondence: [email protected]; Tel.: +82-31-219-2600 Received: 9 July 2019; Accepted: 28 August 2019; Published: 1 September 2019 Abstract: The built-in innate immunity in the human body combats various diseases and their causative agents. One of the components of this system is Toll-like receptors (TLRs), which recognize structurally conserved molecules derived from microbes and/or endogenous molecules. Nonetheless, under certain conditions, these TLRs become hypofunctional or hyperfunctional, thus leading to a disease-like condition because their normal activity is compromised. In this regard, various small-molecule drugs and recombinant therapeutic proteins have been developed to treat the relevant diseases, such as rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, systemic lupus erythematosus, and allergy. Some drugs for these diseases have been clinically approved; however, their efficacy can be enhanced by conventional or targeted drug delivery systems. Certain delivery vehicles such as liposomes, hydrogels, nanoparticles, dendrimers, or cyclodextrins can be employed to enhance the targeted drug delivery. This review summarizes the TLR signaling pathway, associated diseases and their treatments, and the ways to efficiently deliver the drugs to a target site. Keywords: Toll-like receptor; immunological disease; therapeutic; drug delivery method 1. Introduction The immune system in an organism is the protective system combating pathogenic and/or abnormal conditions. Innate and adaptive immune systems are two basic components in vertebrates. Adaptive immunity is mediated by T and B lymphocytes with the help of their antigen-specific receptors that are encoded as a result of hypermutability and rearrangements in a genomic region of the organism. -
Natural Killer Cell Lymphoma Shares Strikingly Similar Molecular Features
Leukemia (2011) 25, 348–358 & 2011 Macmillan Publishers Limited All rights reserved 0887-6924/11 www.nature.com/leu ORIGINAL ARTICLE Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic cd T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro J Iqbal1, DD Weisenburger1, A Chowdhury2, MY Tsai2, G Srivastava3, TC Greiner1, C Kucuk1, K Deffenbacher1, J Vose4, L Smith5, WY Au3, S Nakamura6, M Seto6, J Delabie7, F Berger8, F Loong3, Y-H Ko9, I Sng10, X Liu11, TP Loughran11, J Armitage4 and WC Chan1, for the International Peripheral T-cell Lymphoma Project 1Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA; 2Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA; 3Departments of Pathology and Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China; 4Division of Hematology and Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA; 5College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA; 6Departments of Pathology and Cancer Genetics, Aichi Cancer Center Research Institute, Nagoya University, Nagoya, Japan; 7Department of Pathology, University of Oslo, Norwegian Radium Hospital, Oslo, Norway; 8Department of Pathology, Centre Hospitalier Lyon-Sud, Lyon, France; 9Department of Pathology, Samsung Medical Center, Sungkyunkwan University, Seoul, Korea; 10Department of Pathology, Singapore General Hospital, Singapore and 11Penn State Hershey Cancer Institute, Pennsylvania State University College of Medicine, Hershey, PA, USA Natural killer (NK) cell lymphomas/leukemias are rare neo- Introduction plasms with an aggressive clinical behavior. -
Regulation and Genetic Manipulation of Ligands for the Immunoreceptor NKG2D
Regulation and Genetic Manipulation of Ligands for the Immunoreceptor NKG2D by Benjamin Gregory Gowen A dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Molecular and Cell Biology in the Graduate Division of the University of California, Berkeley Committee in charge: Professor David H. Raulet, Chair Professor Gregory M. Barton Professor Michael Rape Professor Karsten Gronert Spring 2015 Abstract Regulation and Genetic Manipulation of Ligands for the Immunoreceptor NKG2D by Benjamin Gregory Gowen Doctor of Philosophy in Molecular and Cell Biology University of California, Berkeley Professor David H. Raulet, Chair NKG2D is an important activating receptor expressed by natural killer (NK) cells and some subsets of T cells. NKG2D recognizes a family of cell surface protein ligands that are typically not expressed by healthy cells, but become upregulated by cellular stress associated with transformation or infection. Engagement of NKG2D by its ligands displayed on a target cell membrane leads to NK cell activation, cytokine secretion, and lysis of the target cell. Despite the importance of NKG2D for controlling tumors, the molecular mechanisms driving NKG2D ligand expression on tumor cells are not well defined. The work described in this dissertation was centered on the identification of novel regulators of ULBP1, one of the human NKG2D ligands. Using a forward genetic screen of a tumor-derived human cell line, we identified several novel factors supporting ULBP1 expression, and used the CRISPR/Cas9 system to further investigate these hits. Our results showed stepwise contributions of independent pathways working at multiple stages of ULBP1 biogenesis, including transcription of the ULBP1 gene, splicing of the ULBP1 mRNA, and additional co-translational or post-translational regulation of the ULBP1 protein. -
NKG2D and Related Immunoreceptors
NKG2D and related immunoreceptors Roland K. Strong1* and Benjamin J. McFarland2 1Division of Basic Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. North, Seattle, WA 98109 2Department of Chemistry and Biochemistry, Seattle Pacific University, 3307 Third Avenue West, Seattle WA 98119 *email address: [email protected] Abstract NK cells are crucial components of the innate immune system, capable of directly eliminating infected or tumorigenic cells and regulating down-stream adaptive immune responses. Unlike T cells, where the key recognition event driving activation is mediated by the unique T cell receptor (TCR) expressed on a given cell, NK cells express multiple activating and inhibitory cell-surface receptors (NKRs), often with overlapping ligand specificities. NKRs display two ectodomain structural homologies, either immunoglobulin- or C-type lectin-like (CTLD). The CTLD immunoreceptor NKG2D is found on NK cells but is also widely expressed on T cells and other immune system cells, providing stimulatory or co- stimulatory signals. NKG2D drives target cell killing following engagement of diverse, conditionally expressed MHC class I-like protein ligands whose expression can signal cellular distress due to infection or transformation. The symmetric, homodimeric receptor interacts with its asymmetric, monomeric ligands in similar 2:1 complexes, with an equivalent surface on each NKG2D monomer binding extensively and intimately to distinct, structurally divergent surfaces on the ligands. Thus, NKG2D ligand-binding site recognition is highly degenerate, further demonstrated by NKG2D’s ability to simultaneously accommodate multiple non-conservative allelic or isoform substitutions in the ligands. In TCRs, ‘induced-fit’ recognition explains cross-reactivity, but structural, computational, thermodynamic and kinetic analyses of multiple NKG2D–ligand pairs show that rather than classical ‘induced-fit’ binding, NKG2D degeneracy is achieved using distinct interaction mechanisms at each rigid interface: recognition degeneracy by ‘rigid adaptation’. -
Cx3cr1 Mediates the Development of Monocyte-Derived Dendritic Cells During Hepatic Inflammation
CX3CR1 MEDIATES THE DEVELOPMENT OF MONOCYTE-DERIVED DENDRITIC CELLS DURING HEPATIC INFLAMMATION. Supplementary material Supplementary Figure 1: Liver CD45+ myeloid cells were pre-gated for Ly6G negative cells for excluding granulocytes and HDCs subsequently analyzed among the cells that were CD11c+ and had high expression of MHCII. Supplementary Table 1 low/- high + Changes in gene expression between CX3CR1 and CX3CR1 CD11b myeloid hepatic dendritic cells (HDCs) from CCl4-treated mice high Genes up-regulated in CX3CR1 HDCs Gene Fold changes P value Full name App 4,01702 5,89E-05 amyloid beta (A4) precursor protein C1qa 9,75881 1,69E-22 complement component 1, q subcomponent, alpha polypeptide C1qb 9,19882 3,62E-20 complement component 1, q subcomponent, beta polypeptide Ccl12 2,51899 0,011769 chemokine (C-C motif) ligand 12 Ccl2 6,53486 6,37E-11 chemokine (C-C motif) ligand 2 Ccl3 4,99649 5,84E-07 chemokine (C-C motif) ligand 3 Ccl4 4,42552 9,62E-06 chemokine (C-C motif) ligand 4 Ccl6 3,9311 8,46E-05 chemokine (C-C motif) ligand 6 Ccl7 2,60184 0,009272 chemokine (C-C motif) ligand 7 Ccl9 4,17294 3,01E-05 chemokine (C-C motif) ligand 9 Ccr2 3,35195 0,000802 chemokine (C-C motif) receptor 2 Ccr5 3,23358 0,001222 chemokine (C-C motif) receptor 5 Cd14 6,13325 8,61E-10 CD14 antigen Cd36 2,94367 0,003243 CD36 antigen Cd44 4,89958 9,60E-07 CD44 antigen Cd81 6,49623 8,24E-11 CD81 antigen Cd9 3,06253 0,002195 CD9 antigen Cdkn1a 4,65279 3,27E-06 cyclin-dependent kinase inhibitor 1A (P21) Cebpb 6,6083 3,89E-11 CCAAT/enhancer binding protein (C/EBP), -
TLR8 Differences Between Human TLR7 and Synthetic TLR Agonists
Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8 Keith B. Gorden, Kevin S. Gorski, Sheila J. Gibson, Ross M. Kedl, William C. Kieper, Xiaohong Qiu, Mark A. Tomai, This information is current as Sefik S. Alkan and John P. Vasilakos of September 29, 2021. J Immunol 2005; 174:1259-1268; ; doi: 10.4049/jimmunol.174.3.1259 http://www.jimmunol.org/content/174/3/1259 Downloaded from References This article cites 36 articles, 14 of which you can access for free at: http://www.jimmunol.org/content/174/3/1259.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 29, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8 Keith B. Gorden, Kevin S. Gorski, Sheila J. Gibson, Ross M. Kedl,1 William C. -
Comparative Analysis of Human NK Cell Activation Induced by NKG2D and Natural Cytotoxicity Receptors
Eur. J. Immunol. 2004. 34: 961–971 NK cell activation by NKG2D and NCR 961 Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors Pascale Andre ´ 1,RobertaCastriconi2,MarionEsp´eli3, Nicolas Anfossi3,Tiffany Juarez4,SophieHue5, Holli Conway1,Fran¸cois Romagne ´ 1, Alessandra Dondero2, Marina Nanni6, Sophie Caillat-Zucman5, David H. Raulet4,CristinaBottino6,Eric Vivier3, Alessandro Moretta2,7 and Pascale Paul3 1 Innate-Pharma SA, Marseille, France 2 Molecular Immunology laboratories, Dipartimento di Medicina Sperimentale, Sezione di Istologia, University of Genova, Genova, Italy 3 Centre d’Immunologie de Marseille-Luminy, CNRS-INSERM-UniversitedelaM´ ´ editerranee, ´ Marseille, France 4 Department of Molecular and Cell Biology and Cancer Research Laboratory, University of California, Berkeley, USA 5 Laboratoire d’Immunologie and Equipe Avenir INSERM, IFR94, Hopital ˆ Necker, Paris, France 6 Istituto Giannina Gaslini, Genova, Genova, Italy 7 Centro di Eccellenza per le Ricerche Biomediche, University of Genova, Genova, Italy NKG2D and natural cytotoxicity receptors (NCR) are essential recognition structures that mediate NK cell activation. NKG2D and NCR signaling is achieved through membrane asso- ciation with signaling adaptors. The adaptors that associate with NCR — such as CD3 ´ , FcR + and KARAP/DAP12 — bear intracytoplasmic immunoreceptor tyrosine-based activa- tion motifs that activate Syk protein tyrosine kinases. Human NKG2D associates with the DAP10 transmembrane adaptor, which bears a YxxM motif and activates the phosphatidyl- inositol 3-kinase pathway. In the mouse, a short NKG2D-S isoform, generated by Nkg2d alternative splicing, can associate with either DAP10 or KARAP/DAP12. Here, we report that neither short human NKG2D alternative transcripts nor NKG2D association with KARAP/ DAP12 was detected in activated human NK cells. -
Role of NKG2D in Obesity-Induced Adipose Tissue Inflammation and Insulin Resistance Jun-Jae Chung Washington University School of Medicine in St
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2014 Role of NKG2D in obesity-induced adipose tissue inflammation and insulin resistance Jun-Jae Chung Washington University School of Medicine in St. Louis Mary A. Markiewicz Washington University School of Medicine in St. Louis Bojan Polic University of Rijeka School of Medicine Andrey S. Shaw Washington University School of Medicine in St. Louis Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs Recommended Citation Chung, Jun-Jae; Markiewicz, Mary A.; Polic, Bojan; and Shaw, Andrey S., ,"Role of NKG2D in obesity-induced adipose tissue inflammation and insulin resistance." PLoS One.9,10. e110108. (2014). https://digitalcommons.wustl.edu/open_access_pubs/3408 This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact [email protected]. Role of NKG2D in Obesity-Induced Adipose Tissue Inflammation and Insulin Resistance Jun-Jae Chung1, Mary A. Markiewicz1¤, Bojan Polic´2, Andrey S. Shaw1,3* 1 Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America, 2 Department of Histology and Embryology, University of Rijeka School of Medicine, Rijeka, Croatia, 3 Howard Hughes Medical Institute, Washington University School of Medicine, St. Louis, Missouri, United States of America Abstract The early events that initiate inflammation in the adipose tissue during obesity are not well defined. It is unclear whether the recruitment of CD8 T cells to the adipose tissue during onset of obesity occurs through antigen-dependent or - independent processes. -
TLR8 on Dendritic Cells and TLR9 on B Cells Restrain TLR7-Mediated Spontaneous Autoimmunity in C57BL/6 Mice
TLR8 on dendritic cells and TLR9 on B cells restrain TLR7-mediated spontaneous autoimmunity in C57BL/6 mice Benoit Desnuesa,b,c,1, Amanda Beatriz Macedoa,b,c,1, Annie Roussel-Quevala,b,c, Johnny Bonnardela,b,c, Sandrine Henria,b,c, Olivier Demariaa,b,c,2, and Lena Alexopouloua,b,c,3 aCentre d’Immunologie de Marseille-Luminy, Aix-Marseille University UM 2, 13288 Marseille, France; bInstitut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1104, 13288 Marseille, France; and cCentre National de la Recherche Scientifique, Unité Mixte de Recherche 7280, 13288 Marseille, France Edited* by Richard A. Flavell, Yale School of Medicine, Howard Hughes Medical Institute, New Haven, CT, and approved December 18, 2013 (received for review August 5, 2013) Systemic lupus erythematosus (SLE) is a complex autoimmune endosomal localization isolate TLR3, TLR7, TLR8, and disease with diverse clinical presentations characterized by the TLR9 away from self-nucleic acids in the extracellular space, still presence of autoantibodies to nuclear components. Toll-like re- self-RNA or -DNA can become a potent trigger of cell activation ceptor (TLR)7, TLR8, and TLR9 sense microbial or endogenous nucleic when transported into TLR-containing endosomes, and such acids and are implicated in the development of SLE. In mice TLR7- recognition can result in sterile inflammation and autoimmunity, deficiency ameliorates SLE, but TLR8- or TLR9-deficiency exacerbates including SLE (4, 15, 16). The connection of the endosomal the disease because of increased TLR7 response. Thus, both TLR8 TLRs with SLE originates mainly from mouse models, where and TLR9 control TLR7 function, but whether TLR8 and TLR9 act in TLR7 signaling seems to play a central role.